

## REMARKS

Claim 16 has been cancelled from the present application without prejudice to re-filing in a continuation application. New claims 20 and 21 have been added. Claims 1 – 15, and 17 - 21 are currently pending.

### Objections

Claims 1 – 19 were objected to because of informalities. Claims 1, 6, 7, 8, and 11- 14 have been amended to remove an extra “~” in chemical names. Support for the amendment to claims 1, 6, 7, 8, and 11 - 14 can be found in the specification at pages 4 – 6. Claims 2 and 6 have been amended to replace “R<sup>i</sup>” with “R<sup>1</sup>”. Claim 3 has been amended to replace “R” with “R<sup>1</sup>”. Support for the amendments to claims 2, 3, and 6 can be found in the specification at pages 4 – 6. Claims 1 and 14 have been amended to correct typographical errors.

### 35 U.S.C. § 112

Claim 14 was rejected under 35 U.S.C. § 112, second paragraph because the Examiner contended that while the claim is directed to a process for preparing a compound of formula 1 where R<sup>1</sup> is a number of substituents, the claim recites the preparation of a compound wherein R<sup>1</sup> chloro. Applicants respectfully disagree. Claim 14 as originally filed recites the preparation of compound of formula 1 wherein R<sup>1</sup> is chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino and 5-methyl-3-isoxazolylamino. However, for clarity, claim 14 has been amended to recite preparation of a compound wherein R<sup>1</sup> is amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino and 5-methyl-3-isoxazolylamino. New claim 20 is directed to the preparation of a compound of formula 1 wherein R<sup>1</sup> is chloro. Support for the amendment to claim 14 and support for new claims 20 and 21 can be found in the specification at pages 4 – 6, originally filed claim 14, and in the Examples.

Claim 16 was rejected under 35 U.S.C. § 112. Claims 16 has been cancelled. Therefore, the rejection is moot as to claim 16.

It is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

Applicants hereby request a 1-month extension of time to extend the response period up to and including 20 June 2007. The Commissioner is hereby authorized to charge such fees and any other fees required or credit any overpayment to Deposit Account No. 07-1392]

Respectfully submitted,

Dated: June 20, 2007

  
Karen L. Prus

GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: 919-483-2192  
Fax: 919-483-7988

Attorney for Applicant  
Reg. No. 39,337